Guangdong Yinzhu Pharmaceutical Technology

Guangdong Yinzhu Pharmaceutical Technology is a clinical-stage biotechnology company based in Guangzhou, China, serving as an innovative drug research and development arm of the Yangzijiang Pharmaceutical Group. The company focuses on the discovery and development of small molecule therapeutics for central nervous system (CNS) disorders, oncology, and inflammatory diseases. Its lead candidate, YZJ-1139, is a dual orexin receptor antagonist (DORA) that has progressed to Phase 3 clinical trials for the treatment of insomnia. Yinzhu leverages the extensive manufacturing and commercialization resources of its parent company while maintaining a dedicated focus on novel drug discovery. The company's pipeline also includes targeted therapies such as JAK inhibitors and PI3K inhibitors aimed at addressing significant unmet medical needs.